Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights ...

Travere Therapeutics has voluntarily paused subject enrolment in the Phase III HARMONY Study of pegtibatinase to treat classical homocystinuria (HCU), a rare genetic metabolic disorder. This decision ...

This page lists all known medications that could potentially lead to 'Homocystinuria' as a side effect. It's important to note that mild side effects are quite common with medications. The ...

Denovo Sciences Inc, a pioneer in AI-driven drug discovery based on synthetic data, Weill Cornell Medicine-Qatar (WCM-Q), and Sidra Medicine are engaging in a collaboration to identify and develop ...

A new technique, surrogate organism genetics, has been used to “swap” yeast genes with human genes sequenced from patients with homocystinuria to determine the gene variants likely to respond to ...

Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May be ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Orphan Technologies, a company dedicated to helping patients control their homocysteine levels, today announced that the first patients have been treated in a Phase ...

An international research team has published a study in the journal The FEBS Journal that significantly advances the knowledge of a rare hereditary metabolic disease: classical homocystinuria. The ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Orphan Technologies, a company dedicated to helping patients control their homocysteine levels, published study showing that 12,113 patients in the United States are ...